Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases 21,155 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 21,155 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were purchased at an average price of $21.46 per share, with a total value of $453,986.30. Following the transaction, the insider now owns 10,869,786 shares of the company’s stock, valued at $233,265,607.56. The trade was a 0.20 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The stock was bought at an average price of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock. The stock was purchased at an average cost of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock opened at $21.85 on Friday. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of 49.66 and a beta of 0.63. The stock’s 50-day moving average is $25.53 and its 200-day moving average is $32.09. STAAR Surgical has a one year low of $21.13 and a one year high of $52.68.

Analyst Ratings Changes

STAA has been the subject of several research analyst reports. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 7th. Canaccord Genuity Group decreased their target price on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, December 9th. Finally, Stephens raised STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $42.83.

Hedge Funds Weigh In On STAAR Surgical

A number of large investors have recently bought and sold shares of the company. Arcadia Investment Management Corp MI bought a new stake in shares of STAAR Surgical in the third quarter worth $37,000. Quarry LP acquired a new stake in STAAR Surgical in the 3rd quarter valued at $50,000. Quest Partners LLC bought a new stake in STAAR Surgical during the 3rd quarter worth about $128,000. Canada Pension Plan Investment Board acquired a new position in shares of STAAR Surgical during the 2nd quarter worth about $129,000. Finally, Van ECK Associates Corp grew its holdings in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 393 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.